Skip to main content
Log in

Pharmacokinetic analysis of metronomic capecitabine in refractory metastatic colorectal cancer patients

  • SHORT REPORT
  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Summary

The aim of the present study was to assess the pharmacokinetics (PK) of metronomic capecitabine and its metabolites in a population of refractory metastatic colorectal cancer (mCRC) patients. Thirty-four patients (M/F, 22/12) with a diagnosis of mCRC received capecitabine 800 mg p.o. twice a day and cyclophosphamide 50 mg/day p.o. Blood samples were collected at baseline, 15 min, 30 min, 1 h, 1.5 h, 2 h, 3 h and 5 h at day 1 after capecitabine administration. Plasma concentrations of capecitabine and its metabolites were measured by high performance liquid chromatography and the main PK parameters were calculated. Maximum plasma concentrations (Cmax) of capecitabine (11.51 ± 9.73 μg/ml) occurred at 0.5 h, whereas the Cmax of 5′-deoxy-5-fluorocytidine (5’-DFCR; 2.45 ± 2.93 μg/ml), 5′-deoxy-5-fluorouridine (5’-DFUR; 6.43 ± 8.2 μg/ml), and 5-fluorouracil (5-FU; 0.24 ± 0.16 μg/ml) were found at 1 h, 1.5 h and 1 h, respectively. Capecitabine, 5’-DFCR, 5’-DFUR and 5-FU AUCs at day 1 were 21.30 ± 10.78, 5.2 ± 4.6, 19.59 ± 3.83 and 0.66 ± 0.77 hxμg/ml, respectively. In conclusion, low doses of capecitabine were rapidly absorbed and extensively metabolized, achieving measurable plasma concentrations in a heavily pretreated population of patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

Similar content being viewed by others

References

  1. Reigner B, Blesch K, Weidekamm E (2001) Clinical pharmacokinetics of capecitabine. Clin Pharmacokinet 40(2):85–104

    Article  PubMed  CAS  Google Scholar 

  2. Miwa M, Ura M, Nishida M, Sawada N, Ishikawa T, Mori K, Shimma N, Umeda I, Ishitsuka H (1998) Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 34(8):1274–1281

    Article  PubMed  CAS  Google Scholar 

  3. Tabata T, Katoh M, Tokudome S, Hosakawa M, Chiba K, Nakajima M, Yokoi T (2004) Bioactivation of capecitabine in human liver: involvement of the cytosolic enzyme on 5′-deoxy-5-fluorocytidine formation. Drug Metab Dispos 32(7):762–767

    Article  PubMed  CAS  Google Scholar 

  4. Mercier C, Dupuis C, Blesius A, Fanciullino R, Yang CG, Padovani L, Giacometti S, Frances N, Iliadis A, Duffaud F, Ciccolini J (2009) Early severe toxicities after capecitabine intake: possible implication of a cytidine deaminase extensive metabolizer profile. Cancer Chemother Pharmacol 63(6):1177–1180

    Article  PubMed  Google Scholar 

  5. Camiener GW, Smith CG (1965) Studies of the enzymatic deamination of cytosine arabinoside. I Enzyme distribution and species specificity. Biochem Pharmacol 14(10):1405–1416

    Article  PubMed  CAS  Google Scholar 

  6. Schuller J, Cassidy J, Dumont E, Roos B, Durston S, Banken L, Utoh M, Mori K, Weidekamm E, Reigner B (2000) Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother Pharmacol 45(4):291–297

    Article  PubMed  CAS  Google Scholar 

  7. Malet-Martino M, Jolimaitre P, Martino R (2002) The prodrugs of 5-fluorouracil. Curr Med Chem Anticancer Agents 2(2):267–310

    Article  PubMed  CAS  Google Scholar 

  8. Bocci G, Kerbel RS (2016) Pharmacokinetics of metronomic chemotherapy: a neglected but crucial aspect. Nat Rev Clin Oncol 13(11):659–673

    Article  PubMed  CAS  Google Scholar 

  9. Kerbel RS, Kamen BA (2004) The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 4(6):423–436

    Article  PubMed  CAS  Google Scholar 

  10. Andre N, Carre M, Pasquier E (2014) Metronomics: towards personalized chemotherapy? Nat Rev Clin Oncol 11(7):413–431

    Article  PubMed  CAS  Google Scholar 

  11. Penel N, Adenis A, Bocci G (2012) Cyclophosphamide-based metronomic chemotherapy: after 10 years of experience, where do we stand and where are we going? Crit Rev Oncol Hematol 82(1):40–50

    Article  PubMed  Google Scholar 

  12. Andre N, Padovani L, Verschuur A (2010) Metronomic chemotherapy: back to the future! Drug News Perspect 23(2):143–151

    Article  PubMed  Google Scholar 

  13. Woo IS, Jung YH (2017) Metronomic chemotherapy in metastatic colorectal cancer. Cancer Lett 400:319–324

    Article  PubMed  CAS  Google Scholar 

  14. Marmorino F, Cremolini C, Loupakis F, Salvatore L, Schirripa M, Antoniotti C, Desidero TD, Canu B, Orlandi P, Fioravanti A, Masi G, Bocci G, Falcone A (2013) Metronomic capecitabine (cape) and cyclophosphamide (CTX) for refractory metastatic colorectal cancer (mCRC): Results of a phase II trial. J Clin Oncol 31(15_suppl):e14577–e14577

    Google Scholar 

  15. Dhananjeyan MR, Liu J, Bykowski C, Trendel JA, Sarver JG, Ando H, Erhardt PW (2007) Rapid and simultaneous determination of capecitabine and its metabolites in mouse plasma, mouse serum, and in rabbit bile by high-performance liquid chromatography. J Chromatogr A 1138(1–2):101–108

    Article  PubMed  CAS  Google Scholar 

  16. Garg MB, Sevester JC, Sakoff JA, Ackland SP (2002) Simple liquid chromatographic method for the determination of uracil and dihydrouracil plasma levels: a potential pretreatment predictor of 5-fluorouracil toxicity. J Chromatogr B Anal Technol Biomed Life Sci 774(2):223–230

    Article  CAS  Google Scholar 

  17. Simkens LH, van Tinteren H, May A, ten Tije AJ, Creemers GJ, Loosveld OJ, de Jongh FE, Erdkamp FL, Erjavec Z, van der Torren AM, Tol J, Braun HJ, Nieboer P, van der Hoeven JJ, Haasjes JG, Jansen RL, Wals J, Cats A, Derleyn VA, Honkoop AH, Mol L, Punt CJ, Koopman M (2015) Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch colorectal cancer group. Lancet 385(9980):1843–1852

    Article  PubMed  CAS  Google Scholar 

  18. Chaigneau L, Royer B, Montange D, Nguyen T, Maurina T, Villanueva C, Demarchi M, Borg C, Fagnoni-Legat C, Kantelip JP, Pivot X (2008) Influence of capecitabine absorption on its metabolites pharmacokinetics: a bioequivalence study. Ann Oncol 19(11):1980–1981

    Article  PubMed  CAS  Google Scholar 

  19. Milano G, Ferrero JM, Francois E (2004) Comparative pharmacology of oral fluoropyrimidines: a focus on pharmacokinetics, pharmacodynamics and pharmacomodulation. Br J Cancer 91(4):613–617

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  20. Urien S, Rezai K, Lokiec F (2005) Pharmacokinetic modelling of 5-FU production from capecitabine--a population study in 40 adult patients with metastatic cancer. J Pharmacokinet Pharmacodyn 32(5–6):817–833

    Article  PubMed  CAS  Google Scholar 

  21. Vainchtein LD, Rosing H, Schellens JH, Beijnen JH (2010) A new, validated HPLC-MS/MS method for the simultaneous determination of the anti-cancer agent capecitabine and its metabolites: 5′-deoxy-5-fluorocytidine, 5′-deoxy-5-fluorouridine, 5-fluorouracil and 5-fluorodihydrouracil, in human plasma. Biomed Chromatogr 24(4):374–386. https://doi.org/10.1002/bmc.1302

    Article  PubMed  CAS  Google Scholar 

  22. Reigner B, Verweij J, Dirix L, Cassidy J, Twelves C, Allman D, Weidekamm E, Roos B, Banken L, Utoh M, Osterwalder B (1998) Effect of food on the pharmacokinetics of capecitabine and its metabolites following oral administration in cancer patients. Clin Cancer Res 4(4):941–948

    PubMed  CAS  Google Scholar 

  23. Steinbild S, Arends J, Medinger M, Haring B, Frost A, Drevs J, Unger C, Strecker R, Hennig J, Mross K (2007) Metronomic antiangiogenic therapy with capecitabine and celecoxib in advanced tumor patients--results of a phase II study. Onkologie 30(12):629–635. https://doi.org/10.1159/000110580

    Article  PubMed  CAS  Google Scholar 

  24. Lokich J (2004) Capecitabine: fixed daily dose and continuous (noncyclic) dosing schedule. Cancer Investig 22(5):713–717

    Article  CAS  Google Scholar 

  25. Van Cutsem E, Hoff PM, Harper P, Bukowski RM, Cunningham D, Dufour P, Graeven U, Lokich J, Madajewicz S, Maroun JA, Marshall JL, Mitchell EP, Perez-Manga G, Rougier P, Schmiegel W, Schoelmerich J, Sobrero A, Schilsky RL (2004) Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials. Br J Cancer 90(6):1190–1197

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  26. Allegrini G, Di Desidero T, Barletta MT, Fioravanti A, Orlandi P, Canu B, Chericoni S, Loupakis F, Di Paolo A, Masi G, Fontana A, Lucchesi S, Arrighi G, Giusiani M, Ciarlo A, Brandi G, Danesi R, Kerbel RS, Falcone A, Bocci G (2012) Clinical, pharmacokinetic and pharmacodynamic evaluations of metronomic UFT and cyclophosphamide plus celecoxib in patients with advanced refractory gastrointestinal cancers. Angiogenesis 15(2):275–286

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  27. Ciccolini J, Mercier C, Evrard A, Dahan L, Boyer JC, Duffaud F, Richard K, Blanquicett C, Milano G, Blesius A, Durand A, Seitz JF, Favre R, Lacarelle B (2006) A rapid and inexpensive method for anticipating severe toxicity to fluorouracil and fluorouracil-based chemotherapy. Ther Drug Monit 28(5):678–685

    Article  PubMed  CAS  Google Scholar 

  28. Di Paolo A, Del Re M, Arrigoni E, Di Desidero T, Rofi E, Danesi R, Bocci G (2017) Pharmacokinetic markers of 5-fluorouracil toxicity in clinical trials and real world. Clinical Cancer Drugs 4(2):82–92

    Google Scholar 

Download references

Acknowledgements

The authors wish to thank A. Di Paolo, R. Danesi, L. Salvatore, patients and their families for their participation to the study, which was funded by the Istituto Toscano Tumori (ITT).

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Guido Bocci.

Ethics declarations

Conflict of interest

Authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Di Desidero, T., Orlandi, P., Fioravanti, A. et al. Pharmacokinetic analysis of metronomic capecitabine in refractory metastatic colorectal cancer patients. Invest New Drugs 36, 709–714 (2018). https://doi.org/10.1007/s10637-018-0579-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10637-018-0579-8

Keywords

Navigation